Wantai Biotech’s Clinical Trial Application for Recombinant Trivalent Rotavirus Subunit Vaccine Accepted for Review
December 26, 2025
Source: drugdu
27
Beijing Business Today – On December 25, Wantai Biotech announced that its wholly-owned subsidiary, Xiamen Wantai Kangtai Biotech Co., Ltd., received the "Acceptance Notice", an administrative licensing document issued by the National Medical Products Administration (NMPA). The clinical trial application for the company’s "Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)" has been accepted for review.
According to the announcement, this product is a recombinant protein vaccine produced using genetic engineering recombination technology and an Escherichia coli expression system. Its main active component is a truncated rotavirus spike protein VP4.
Reference：https://finance.eastmoney.com/a/202512253601968277.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovative Drug KarXT® (Karigel®) Approved in China December 26, 2025
- Xueji Biotech Completes Over RMB 100 Million Initial Close of Series B1 Equity Funding and Over RMB 100 Million in Debt Funding December 26, 2025
- Just 1 minute! Roche’s bispecific antibody subcutaneous injection formulation receives FDA approval for market launch December 26, 2025
- Pfizer loses out in hemophilia December 26, 2025
- Maiwei Biotech’s new monoclonal antibody drug has received FDA approval to begin Phase 2a clinical trials for COPD December 26, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
